Login
Companies $EW
$107.11 +$0.00 (0.0%) After hours
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp

edwards.com

What Do They Do?

Sells surgical and catheter-based heart valve replacement and repair systems to hospitals and clinicians treating cardiovascular disease.

How Do They Make Money?

The company sells heart devices directly or through consignment; direct sales are completed at delivery, while consigned sales are completed when a device is implanted or used.

revenue
SegmentShareRevenue
Transcatheter Aortic Valve Replacement
Sold outright

74%
FY2022: 79%
Transcatheter Mitral and Tricuspid Therapies
Sold outright
9.1%
FY2022: 2.6%
Surgical Structural Heart
Sold outright

17%
FY2022: 19%

Who Are Their Customers?

Hospitals and clinical teams—including physicians, nurses and hospital purchasing staff—are customers. U.S. sales are mostly direct; outside the U.S., sales go through direct sales forces and independent distributors.

Do Revenues Turn Into Profits?

Yes. It kept 18 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.

Operating income, FY2025
21% of revenue
▼ −8% vs FY2024 ($1.4B, 25%)
Net income, FY2025
18% of revenue
▼ −74% vs FY2024 ($4.2B, 77%)
Free cash flow, FY2025
22% of revenue
▲ +361% vs FY2024 ($289.9M, 5%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +10%
vs $1.6B in Q3 FY2025
Net income
▲ +6%
vs $291.1M in Q3 FY2025
Transcatheter Aortic Valve Replacement share of revenue vs 74.0% in Q3 FY2025
  • Jul 23, 2026 Raised sales growth and TMTT sales guidance Total company constant-currency sales growth guidance rose to 10% to 11%; TMTT sales guidance rose to $760 to $780 million.
  • May 4, 2026 Appointed Theodora Mistras as CFO Mistras succeeded Scott Ullem, effective May 29, 2026.

Growing. Revenue grew 16% in 4 years, from $5.2B in FY2021 to $6.1B in FY2025, about 4% a year.

Exited critical care monitoring The older report included critical-care monitoring alongside heart therapies; the latest describes structural-heart product groups and says the Critical Care business was sold.

Broader commercial mitral and tricuspid therapies The older report described some transcatheter repair systems as commercially available while replacement technologies remained in development; the latest describes commercial repair and replacement therapies.

Revenue over time
Transcatheter Aortic Valve Replacement Transcatheter Mitral and Tricuspid Therapies Surgical Structural Heart Critical Care
$10B$5B$0

Who Do They Compete With?

Competes with Medtronic and Abbott

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support